


once-daily
moxatag[®]
 (amoxicillin extended-release tablets)

*Once-Daily Moxatag
 Amoxicillin Therapy Refined*



TABLET AND BOTTLE SHOWN ARE NOT ACTUAL SIZE

- Extended-release tablets efficiently deliver amoxicillin using a once-daily dose of 775 mg for 10 days¹
- Proven efficacy for the treatment of tonsillitis/pharyngitis secondary to *S. pyogenes* in adults and pediatric patients ≥ 12 years of age¹
- Provides once-daily dosing: it is important in antibiotic therapy to take every dose prescribed^{2,3}
- Favorable safety profile with observed minimal GI upset¹



NDC #	11042-0142-03 or 68453-0142-03
Bottle Size	30 Tablets
Cardinal	4143467
McKesson	329-7538
Amerisource Bergen	729467

Must be taken within one hour of completing a meal.

**To place your order, please contact your wholesaler or Victory Customer Service:
 Phone: 1-866-427-6819 ■ Fax: 1-866-427-6820**

Important Safety Information

Use caution in patients with known serious hypersensitivity to amoxicillin or to other drugs in the same class or patients who have demonstrated anaphylactic reactions to beta-lactams. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy. If an allergic reaction occurs, Moxatag[®] should be discontinued and appropriate therapy instituted. *Clostridium difficile* Associated Diarrhea (CDAD) has been reported with nearly all antibacterial agents, including amoxicillin, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, Moxatag[®] should be discontinued and appropriate therapy instituted. The possibility of superinfections with mycotic or bacterial pathogens should be kept in mind during therapy. If superinfections occur, Moxatag[®] should be discontinued and appropriate therapy instituted. The most common drug-related adverse reactions (incidence >1.0%) are vulvovaginal mycotic infection, diarrhea, nausea, vomiting and headache.

Please see accompanying full Prescribing Information.

References: 1. Moxatag[®] Prescribing Information. MiddleBrook Pharmaceuticals, Inc. 2008. 2. Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. *J Antimicrob Chemother.* 2002;49(6):897-903. 3. Sclar DA, Tartaglione TA, Fine MJ. Overview of issues related to medical compliance with implications for the outpatient management of infectious diseases. *Infect Agents Dis.* 1994;3(5):266-273.